Novo Nordisk Sues Eli Lilly Over GLP-1 Ads
Novo Nordisk Sues Eli Lilly alleges ads omitted higher-dose data and seeks injunction that could force ad removals and raise GLP-1 compliance risk.
KEY TAKEAWAYS
- Novo filed suit alleging Lilly's nationwide ads omitted newer higher-dose data, including Wegovy 7.2 mg.
- The complaint targets dose comparator omissions and selective comparisons that Novo says mislead consumers.
- Novo seeks a permanent injunction and corrective advertising to remove or correct the disputed comparative claims.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
On July 21, 2026, Novo Nordisk Inc. (NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (LLY), accusing Lilly of using outdated dose comparisons and omitting newer, higher-dose data in its nationwide direct-to-consumer advertising for GLP-1 drugs.
Allegations of Misleading Advertising
Novo Nordisk alleges that Lilly’s advertising campaigns for Zepbound and Mounjaro are false and materially misleading because they rely on outdated clinical studies and selectively compare doses to create an impression of product superiority. The complaint focuses on dose comparisons and the omission of newer, higher-dose options.
Specifically, Novo says Lilly’s Zepbound ads compare the 10- and 15-milligram doses to lower doses of Novo’s Wegovy (semaglutide), excluding the FDA-approved 7.2 mg Wegovy dose authorized in March 2026. That dose’s trials showed an average 19.0% body-weight reduction, roughly 47 pounds. Novo notes there is no head-to-head clinical trial comparing the highest approved doses of Zepbound and Wegovy.
Similarly, Lilly’s Mounjaro ads compare the 15-milligram dose to Ozempic at a 1-milligram maintenance dose, omitting the FDA-approved 2-milligram maintenance dose of Ozempic, approved more than four years ago. Novo contends this selective comparison misleads consumers about product effectiveness.
Novo says the Zepbound campaign ran during major global sports broadcasts and on TikTok and Facebook, contributing to significant consumer confusion about the relative effectiveness of the drugs.
Novo’s general counsel stated that Lilly’s ads highlight roughly 50 pounds of weight loss for Zepbound versus about 33 pounds for Wegovy, despite no direct trial comparing the highest doses. He added that separate late-stage trials showed average weight loss of about 48 pounds for Zepbound and 47 pounds for Wegovy, a difference far smaller than Lilly’s advertising suggests.
Legal Claims and Relief Sought
Novo Nordisk seeks a permanent injunction requiring Lilly to remove the challenged comparative advertising across all platforms and to conduct a corrective advertising campaign. The company said it will pursue a preliminary injunction if Lilly does not voluntarily withdraw the ads. The complaint cites violations of federal and state false advertising and unfair competition laws, including the Lanham Act.
Novo also said it sent Lilly a formal cease-and-desist letter, which Lilly declined to honor, instead adding what Novo describes as an inadequate disclaimer. Novo characterized Lilly’s conduct as a nationwide pattern of deceptive advertising intended to confuse consumers.
The lawsuit unfolds amid intensifying competition in the GLP-1 injectable market. Novo markets Wegovy and Ozempic, while Lilly sells Zepbound and Mounjaro. Both companies have pursued legal actions related to GLP-1 promotion and distribution, and regulators have increased scrutiny of compounding and promotional practices in the sector.
This suit could create near-term marketing and compliance risks for Lilly and add reputational pressure across the GLP-1 category.
